How do Cdk5/p35/p39 mutations affect both nucleokinesis and leading edge formation during migration?

OPEN

The abstract notes that Cdk5 mutations cause migration defects compatible with defective nucleokinesis, but also likely affect leading edge formation. The dual mechanism and relative contributions are unclear, limiting therapeutic targeting. Gap type: unexplained_observation Source paper: Neuronal migration. (2001, Mech Dev, PMID:11429281)

Priority: 0.75 Domain: neurodevelopment Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: How do Cdk5/p35/p39 mutations affect both nucleokinesis and leading edge formation during migration? is a 0.75 priority gap in neurodevelopment. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How do Cdk5/p35/p39 mutations affect both nucleokinesis and leading edge formation during migration? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
0%
Resolution
0
Mechanistic Families
Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (2)

Cdk5synaptophysin phosphorylationCdk5SV2A phosphorylation

associated with and was activated by (1)

10588725Cdk5

associates with and is activated by (1)

10588725Cdk5

causes (2)

PAFAH1B1Cdk5MICROTUBULESCdk5

data in (2)

Cdk5benchmark_ot_ad_answer_key:CDK5benchmark_ot_ad_answer_key:CDK5Cdk5

is a functional homologue of (1)

10588725Cdk5

is activated by (1)

10588725Cdk5

therapeutic target (11)

FGF13Cdk5MAPTCdk5MMP2Cdk5CDK5R2Cdk5SCN2BCdk5
▸ Show 6 more
🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps